Skip to main content
Triangle logo TriangleGet started

Pembrolizumab (NCT07773987)

Immunotherapy and Nodal-Sparing Irradiation for T-Cell Induction and Unmasking of Tumor Antigenicity in the Microenvironment for Head and Neck Cancer: a one-minute explainerNCT077739871 min

Pembrolizumab trial for Head and Neck Cancer Squamous Cell Carcinoma (NCT07773987). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with resectable oral-cavity cancer or HPV-negative oropharyngeal cancer. Tumors must be T3–T4 or node-positive, with PD-L1 CPS of at least one.

The idea: give pembrolizumab, which blocks PD-1 immune suppression, plus radiation before surgery. Random assignment determines whether radiation also covers uninvolved draining lymph nodes. Everyone receives two pembrolizumab cycles before radiation and two afterward. Serial biopsies study immune changes; MRI is optional.

This phase 2 study plans 20 patients. Musaddiq Awan leads at Froedtert in Milwaukee, the sole recruiting US site. Researchers assess tumor disappearance at surgery.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.